天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (4): 404-407.doi: 10.11958/20150383

• 专题研究-乳腺肿瘤 • 上一篇    下一篇

乳腺癌预后生物标志物研究进展

韩璐， 宋丰举， 陈可欣△   

  1. 天津医科大学肿瘤医院， 国家肿瘤临床医学研究中心， 天津市 “肿瘤防治” 重点实验室肿瘤分子流行病与生物统计研究室 （邮编 300060）
  • 收稿日期:2015-12-08 修回日期:2016-01-08 出版日期:2016-04-15 发布日期:2016-05-20
  • 通讯作者: △通讯作者 E-mail: chenkexin@tjmuch.com E-mail:chenkexin1963@yahoo.com
  • 作者简介:韩璐 （1989）， 女， 硕士在读， 主要从事肿瘤分子流行病学研究
  • 基金资助:
    国家自然科学基金资助项目 （81473039， 81172762）

Research advances in biomarkers of the prognosis of breast cancer

HAN Lu, SONG Fengju, CHEN Kexin△   

  1. Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hosipital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
  • Received:2015-12-08 Revised:2016-01-08 Published:2016-04-15 Online:2016-05-20
  • Contact: △Corresponding Author E-mail: chenkexin@tjmuch.com E-mail:chenkexin1963@yahoo.com

PDF (PC)

3989

摘要： 摘要： 乳腺癌是世界范围内女性发病率最高的恶性肿瘤， 也是导致女性癌症相关死亡的最主要原因。近些年乳腺癌患者数量呈逐年增加趋势， 严重威胁女性的生命健康和生活质量。因此， 乳腺癌预后的研究对乳腺癌患者意义深远。随着分子生物学的发展， 一些分子生物学标志物被发现与乳腺癌患者预后有关， 这使得更准确、 有效地评估乳腺癌患者的预后成为可能。本文旨在对乳腺癌预后生物标志物的研究进展作一综述。

关键词: 乳腺肿瘤, 预后, 生物学标记, 综述, miRNA-21, miRNA-210, CXCR4, ALDH1A1, BCL2, BRCA1/BRCA2

Abstract: Abstract： Breast cancer has become the most common malignant tumor and the major cause of cancer-related death for women around the world. The number of patients shows an increasing trend recently. Breast cancer is a big threaten to wom⁃ en’ s health and quality of life. With the development of molecular biology, molecular biomarkers have been found assiciated with prognosis in patients with breast cancer, which makes it possible to predict cancer patient survival precisely and practi⁃ cally. This review summarized those new developments of biomarkers on the prognosis of breast cancer.

Key words: breast neoplasms, prognosis, biological markers, review, miRNA-21, miRNA-210, C-X-C chemokine receptor type 4, aldehyde dehydrogenase 1 family, member A1, B-cell lymphoma-2, BRCA1/BRCA2